Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-03

Clinical Trial Update: A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents [Phase 3]

View source ↗

Summary

Phase 3 multicenter study evaluating safety and immunogenicity of a live-attenuated chikungunya vaccine in adolescents; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Chikungunya live-attenuated vaccine (Butantan Institute) (live-attenuated chikungunya vaccine)

Snippet

Sponsor: Butantan Institute | Conditions: Chikungunya | Phase 3 | Status: COMPLETED